These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species. Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571 [TBL] [Abstract][Full Text] [Related]
31. Antileishmanial activity of human red blood cells containing formycin A. Berman JD; Gallalee JV J Infect Dis; 1985 Apr; 151(4):698-703. PubMed ID: 3973416 [TBL] [Abstract][Full Text] [Related]
32. Epidemiological studies on American leishmaniasis in Ceará State, Brazil. Molecular characterization of the Leishmania isolates. Vasconcelos IA; Vasconcelos AW; Momen H; Grimaldi G; Alencar JE Ann Trop Med Parasitol; 1988 Dec; 82(6):547-54. PubMed ID: 3256276 [TBL] [Abstract][Full Text] [Related]
33. The effect of formycin B on mRNA translation and uptake of purine precursors in Leishmania mexicana. Nolan LL; Berman JD; Giri L Biochem Int; 1984 Aug; 9(2):207-18. PubMed ID: 6207832 [TBL] [Abstract][Full Text] [Related]
34. S-nitrosoglutathione (GSNO) is cytotoxic to intracellular amastigotes and promotes healing of topically treated Leishmania major or Leishmania braziliensis skin lesions. Costa IS; de Souza GF; de Oliveira MG; Abrahamsohn Ide A J Antimicrob Chemother; 2013 Nov; 68(11):2561-8. PubMed ID: 23788476 [TBL] [Abstract][Full Text] [Related]
35. [Experimental chemotherapy in hamsters, using paromomycin against 2 isolates of Leishmania mexicana and Leishmania braziliensis]. Rezzano S; Moreno G; Scorza JV Rev Cubana Med Trop; 1982; 34(1):34-45. PubMed ID: 6750713 [No Abstract] [Full Text] [Related]
36. Molecular typing reveals the co-existence of two transmission cycles of American cutaneous leishmaniasis in the Andean Region of Venezuela with Lutzomyia migonei as the vector. Torrellas A; Ferrer E; Cruz I; Lima H; Delgado O; Rangel JC; Bravo JA; Chicharro C; Llanes-Acevedo IP; Miles MA; Feliciangeli MD Mem Inst Oswaldo Cruz; 2018 Dec; 113(12):e180323. PubMed ID: 30540021 [TBL] [Abstract][Full Text] [Related]
37. Leishmaniasis in the major endemic region of Plurinational State of Bolivia: Species identification, phylogeography and drug susceptibility implications. Bilbao-Ramos P; Dea-Ayuela MA; Cardenas-Alegría O; Salamanca E; Santalla-Vargas JA; Benito C; Flores N; Bolás-Fernández F Acta Trop; 2017 Dec; 176():150-161. PubMed ID: 28751163 [TBL] [Abstract][Full Text] [Related]
38. Cutaneous leishmaniasis in mice: resistance to glucan immunotherapy, either alone or combined with chemotherapy. Avila JL; Biondo F; Monzón H; Convit J Am J Trop Med Hyg; 1982 Jan; 31(1):53-9. PubMed ID: 7058978 [TBL] [Abstract][Full Text] [Related]
39. [Experimental models of cutaneous leishmaniasis in laboratory animals]. Pleskanovskaia SA Parazitologiia; 1986; 20(2):120-5. PubMed ID: 3714297 [TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo activity of meglumine antimoniate produced at Farmanguinhos-Fiocruz, Brazil, against Leishmania (Leishmania) amazonensis, L (L.) chagasi and L (Viannia) braziliensis. Morais-Teixeira Ed; Carvalho AS; Costa JC; Duarte SL; Mendonça JS; Boechat N; Rabello A Mem Inst Oswaldo Cruz; 2008 Jun; 103(4):358-62. PubMed ID: 18660990 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]